Table 3.

Adjusted risk of readmission and mortality associated with the intervention

	Only patients with hepatic encephalopathy		Whole cohort
	Readmission risk Adjusted sHR	Morality risk Adjusted sHR	Readmission risk Adjusted sHR	Morality risk Adjusted sHR
Intervention period	0.63 (0.48–0.82)	0.82 (0.66–1.03)	0.77 (0.65–0.91)	0.80 (0.67–0.95)
Ascites	0.89 (0.68–1.18)	1.25 (1.00–1.55)	0.98 (0.82–1.16)	1.42 (1.19–1.69)
MELD (per point)	1.01 (0.99–1.03)	1.04 (1.03–1.06)	1.01 (0.99–1.02)	1.05 (1.04–1.07)
Age (per yr)	1.01 (0.99–1.02)	1.03 (1.02–1.04)	1.00 (1.00–1.01)	1.03 (1.03–1.04)
TIPS	0.70 (0.33–1.49)	0.91 (0.51–1.62)	0.84 (0.53–1.32)	0.77 (0.47–1.28)
Albumin (per g/dL)	1.08 (0.84–1.38)	0.61 (0.49–0.75)	1.07 (0.93–1.22)	0.55 (0.47–0.63)

The risk of readmission and mortality are modeled using a Fine-Gray competing risk framework. Bolded values are statistically significant.

MELD, model for end-stage liver disease; sHR, subdistribution hazard ratio; TIPS, transjugular intrahepatic portosystemic shunt.